Core Viewpoint - The article explores the rich history and cultural significance of traditional Chinese medicine brand Tong Ren Tang, emphasizing its commitment to quality and community service over centuries [1][4][7]. Group 1: Company History and Philosophy - Tong Ren Tang was founded during the Kangxi era of the Qing Dynasty by Le Xianyang, initially named "Tong Ren Tang Pharmacy" [4]. - The brand has a legacy of over 357 years, known for its high-quality herbal medicines and adherence to traditional manufacturing principles [4][5]. - The motto "同修仁德 济世养生" reflects the company's dedication to benevolence and health care for the public [4][7]. Group 2: Product Offerings - The store offers a wide range of essential health products, including remedies for common ailments such as colds and digestive issues, particularly during the winter-spring transition [5][6]. - Classic formulas like Liu Wei Di Huang Wan and its variations are available, showcasing the brand's commitment to traditional Chinese medicine [6]. - The store also features a cultural section with creative products that appeal to tourists, enhancing the shopping experience [6]. Group 3: Community Engagement and Cultural Significance - Tong Ren Tang has a history of community involvement, such as providing lighting for safe passage home in the past, which has ingrained its name in the public consciousness [7]. - The company continues to support cultural initiatives, such as the "Tong Ren Literature Academy," fostering literary talent among youth [7]. - The upcoming live event aims to discuss the history and cultural impact of old brands like Tong Ren Tang, promoting traditional Chinese culture [8][9].

Core Viewpoint - A significant number of traditional Chinese medicine (TCM) products are at risk of being eliminated from the market due to new regulatory requirements that will take effect in July 2026, which mandate clearer safety information in product descriptions [3][10]. Industry Overview - The new regulations, effective from July 2023, require that any TCM product with unclear safety information (labeled as "unclear") will not be eligible for re-registration after July 1, 2026 [3][10]. - Approximately 75% of TCM products currently on the market have safety information marked as "unclear," which poses a substantial risk of elimination for these products [5][10]. Market Impact - The impending regulatory changes are expected to lead to a significant reshuffling of market shares within the TCM industry, as many companies may not be able to meet the new requirements [10][11]. - Notable products facing potential withdrawal include those with substantial sales figures, such as Longmu Bone Strengthening Granules, which is projected to exceed 1 billion yuan in retail sales in 2024 but has unclear safety information [7][10]. Regulatory Context - The regulatory changes aim to enhance the quality of TCM products rather than a blanket elimination of all products, allowing companies to submit additional research and safety reports to comply [10][12]. - The policy encourages companies to invest in research and development to clarify the efficacy and safety of their products, thereby improving the overall scientific standards of TCM [12][13]. Future Developments - Many leading TCM companies have already begun to prepare for compliance with the new regulations, with some having successfully updated their product safety information [14]. - The regulatory framework is expected to foster a more competitive environment, potentially benefiting companies that can adapt and innovate while disadvantaging those that cannot meet the new standards [11][12].

Core Viewpoint - ST Xiangxue has been facing significant financial challenges, including ongoing lawsuits and a history of losses, leading to a pre-restructuring process initiated due to its inability to meet debt obligations [1][5][7]. Financial Performance - The company's revenue has declined from over 3 billion yuan in 2020 to over 1.8 billion yuan in 2024 [2]. - The net profit attributable to shareholders has been negative for four consecutive years, with losses of -677 million yuan, -530 million yuan, -389 million yuan, and -859 million yuan from 2021 to 2024 [2]. - The cumulative non-recurring net profit from 2017 to 2024 is approximately -2.511 billion yuan, with only one profitable year in 2020 [2]. 2025 Performance Forecast - For 2025, the company expects a net profit loss between 635 million yuan and 934 million yuan, compared to a loss of 859 million yuan in the previous year [2]. - The anticipated non-recurring net profit loss for 2025 is projected to be between 612 million yuan and 899 million yuan [2]. Factors Affecting Performance - The company faces significant financial burdens, including short-term and long-term borrowings amounting to approximately 250 million yuan in financial expenses [3]. - Fixed asset depreciation and amortization are expected to impact around 200 million yuan [3]. - Asset impairment tests are projected to require approximately 130 million yuan for inventory, construction in progress, fixed assets, and development expenditures [3]. - Legal and overdue interest expenses are estimated to be around 220 million yuan [4]. - Non-recurring gains and losses are expected to influence net profit by about 30 million yuan [5]. Pre-restructuring Process - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [5]. - The pre-restructuring period was initially set for three months but has been extended multiple times, with the latest extension to January 11, 2026 [5]. Regulatory Issues - The company has faced administrative penalties for information disclosure violations, resulting in a fine of 6 million yuan and warnings to its actual controller [7]. - The stock was suspended for one day due to these violations and has been placed under risk warnings, changing its name to ST Xiangxue [7]. Market Performance - As of February 6, ST Xiangxue's stock price was 9.50 yuan per share, with a total market capitalization of 6.282 billion yuan [8].

Core Viewpoint - The new regulations for traditional Chinese medicine (TCM) registration, referred to as the "death clause," will require that key safety information be clarified by July 1, 2026, or the products will face delisting. However, many industry insiders view this as an opportunity for the industry to eliminate "zombie approvals" that are no longer commercially viable [1][2][4]. Group 1: Regulatory Changes - The "New Regulations for TCM Registration" will take effect on July 1, 2026, mandating that any TCM product with unclear safety information will not be re-registered [2][3]. - Most of the TCM products likely to be eliminated are considered "zombie approvals," which are low-value, highly homogeneous products with minimal or zero market sales [2][4]. - The cost for updating safety information for TCM products ranges from thousands to tens of thousands of yuan, with an additional application fee of 9,600 yuan per approval [3][6]. Group 2: Industry Response - Industry experts believe that the impact of the new regulations on the overall sales volume of TCM will be minimal, as many products are already in excess supply [4][6]. - Companies are expected to take advantage of the three-year buffer period to either update their products or voluntarily abandon non-core approvals [10][11]. - The time frame for compliance is seen as generous, allowing companies ample opportunity to meet the new requirements without significant financial strain [8][10]. Group 3: Market Dynamics - The upcoming adjustments to the national essential drug list and the TCM centralized procurement process are viewed as more pressing concerns for the industry than the new registration regulations [10][11]. - The centralized procurement process, set to take place in November 2025, will involve 90 products and a market scale of over 45 billion yuan, raising concerns about future pricing and competition [11][12]. - The adjustment of the essential drug list is anticipated to be a critical window for TCM companies, with significant implications for core product viability and profitability [12].

Core Viewpoint - The implementation of the new regulation by the National Medical Products Administration (NMPA) will phase out traditional Chinese medicine (TCM) products with ambiguous safety information, marking a significant shift towards quality over quantity in the TCM industry [1][4]. Group 1: Regulation Impact - The new regulation, referred to as the "life and death clause" for TCM, will take effect on July 1, 2026, and will disallow re-registration of TCM products that have any safety information marked as "unclear" after a three-year grace period [1][4]. - Over 70% of the approximately 57,000 approved TCM products currently have safety information issues, which will lead to a significant reduction in market products, estimated at 30%-40% [2][4]. Group 2: Consumer Safety - Existing TCM products, such as Ban Lan Gen and Lianhua Qingwen, will not be directly affected by the new regulation, allowing consumers to continue using them [3]. - Companies are proactively investing in post-marketing safety evaluations to ensure compliance with the new standards before the deadline [3]. Group 3: Industry Transformation - The regulation signifies a transition for the TCM industry from a focus on quantity to prioritizing quality, with an expected 20%-30% of TCM approvals likely to exit the market in the next 3-5 years [4]. - The cost of compliance for companies may increase due to the need for safety evaluations, but this is not expected to lead to widespread price hikes for TCM products [5][6]. Group 4: Market Dynamics - The market concentration is expected to increase as low-market-share products exit, allowing leading companies to fill the gap with quality products [6]. - The NMPA has established communication mechanisms to support companies in their research efforts and expedite the review process for critical products [6].

Core Viewpoint - The new regulation from the National Medical Products Administration (NMPA) will eliminate ambiguous safety information in traditional Chinese medicine (TCM) product labels, significantly impacting over 70% of existing TCM approvals by 2026 [1][2]. Group 1: Background and Current Situation - The regulation, referred to as the "life and death clause" for TCM, will take effect on July 1, 2026, and aims to address the lack of safety information in TCM product labels [1]. - Currently, there are approximately 57,000 approved TCM products in China, with over 40,000 labels indicating "unclear" safety information in categories such as contraindications and adverse reactions [2]. Group 2: Impact on TCM Products - The regulation is expected to reduce the number of marketable TCM products by 30%-40%, primarily affecting those with unclear clinical value and high safety risks [2]. - Existing products on the market, such as Ban Lan Gen and Lianhua Qingwen, will not be directly affected and can continue to be used by consumers [3]. Group 3: Industry Transformation - The regulation signifies a shift in the TCM industry from quantity expansion to quality prioritization, addressing issues of low clinical value and redundancy among TCM products [4]. - An estimated 20%-30% of TCM approvals may exit the market in the next 3-5 years due to the new registration requirements [4]. Group 4: Cost Implications for Companies - Companies will face increased research costs to comply with the new safety evaluation requirements, which can range from hundreds of thousands to millions of yuan per product [6]. - Despite the increased costs, experts believe that this will not lead to a significant rise in TCM prices due to market competition and the potential for cost dilution through scale production [7]. Group 5: Long-term Industry Outlook - The regulation is seen as a necessary step for the modernization of TCM, aligning with international practices for drug safety information [7]. - The NMPA has established communication mechanisms and support channels to assist companies in meeting the new requirements, particularly for urgently needed products [7].

Core Viewpoint - The upcoming regulatory changes in traditional Chinese medicine (TCM) are perceived as a necessary industry "slimming down," primarily targeting "zombie approvals" that have little to no market presence, rather than posing a significant threat to the overall market supply [1][3]. Regulatory Changes - The new regulations, effective from July 1, 2026, stipulate that if any safety information such as contraindications or adverse reactions remains "unclear" in the product's instructions after three years, the drug will not be eligible for re-registration [3][10]. - Most of the approvals expected to be eliminated are considered "zombie approvals," which are low-value, highly homogeneous products with negligible or zero market sales [3][4]. Industry Response - Industry insiders express that the costs associated with updating the required safety data are manageable, with estimates ranging from several thousand to tens of thousands of yuan per approval [4][7]. - Companies are likely to abandon these "zombie approvals" voluntarily, as they represent ongoing liabilities without significant market impact [5][9]. Market Dynamics - The real concern for the industry lies in the ongoing centralized procurement of TCM and the upcoming adjustments to the national essential drug list, which will significantly influence the core profits and survival of companies [10][11]. - The centralized procurement process, set to include 90 products with a market scale of over 45 billion yuan, raises questions about the future pricing and competitiveness of TCM products [10][11]. Future Outlook - The regulatory timeline provides a lengthy window for companies to adapt, with many already completing re-registration for key products [6][8]. - The adjustments to the essential drug list are anticipated to be more impactful than the registration regulations, as they will determine which products can access the main hospital channels [10][11].

Core Viewpoint - The new regulations for traditional Chinese medicine (TCM) registration, effective July 1, 2026, are perceived as a "survival deadline" for TCM products, requiring clear safety information or facing market exit. However, the industry views this as an opportunity to eliminate "zombie approvals" that have little market value and are not actively sold [1][2]. Group 1: Regulatory Changes - The new regulation mandates that if any safety information in TCM product labels remains "unclear" after three years, re-registration will be denied, leading to potential market exit for those products [2][3]. - Most of the approvals likely to be eliminated are considered "zombie approvals," which are low-value, highly homogeneous products with minimal or zero market sales, thus not impacting the overall market supply [2][3]. - The cost for companies to update their product information to comply with the new regulations is manageable, ranging from thousands to tens of thousands of yuan, with a registration fee of 9,600 yuan per approval [2][3]. Group 2: Industry Response - Industry insiders believe that the impact of the new regulations on total sales volume will be minimal, as many companies are already prepared for the changes and have completed re-registration for key products [4][5]. - The time frame provided by the new regulations is considered sufficient for companies to adapt, with many already having completed necessary updates for core products [6][7]. - The registration process is seen as a manageable task rather than a high-cost project, with companies able to utilize existing databases and literature to fulfill safety data requirements [5][6]. Group 3: Market Dynamics - The upcoming centralized procurement of TCM and adjustments to the national essential drug list are viewed as more significant threats to the industry than the registration regulations, with potential impacts on core product profitability [7][8]. - The centralized procurement process is expected to reshape market dynamics, as it may favor unique products while creating challenges for demonstrating clinical equivalence among similar TCM products [8][9]. - The adjustment of the essential drug list is anticipated to be a critical period for TCM companies, with significant implications for their future development and market positioning [9].

Core Viewpoint - The new regulation from the National Medical Products Administration (NMPA) will eliminate ambiguous safety information in traditional Chinese medicine (TCM) product labels, significantly impacting over 70% of existing TCM approvals by 2026 [1][2]. Group 1: Background and Purpose of the Regulation - The regulation aims to address the safety information gaps in TCM product labels, promoting high-quality development in the TCM industry [2]. - Approximately 57,000 TCM approvals exist in China, with over 40,000 labels indicating "not clear" for contraindications, adverse reactions, or precautions [2]. - The regulation will primarily affect TCM products with unclear clinical value and high safety risks, as well as traditional formulations lacking modern research data [2]. Group 2: Impact on Existing Products - Current TCM products in circulation, such as Ban Lan Gen and Lianhua Qingwen, will not be directly affected, allowing consumers to continue using them [3]. - The regulation applies to the re-registration process, meaning existing stock can still be sold legally [3]. - Leading companies like Yiling Pharmaceutical and Baiyunshan Pharmaceutical Group are proactively investing in post-market safety evaluations to meet the new standards [3]. Group 3: Industry Transformation - The regulation signifies a shift in the TCM industry from quantity expansion to quality prioritization, addressing issues of low clinical value and redundancy among TCM products [4]. - An estimated 20%-30% of TCM approvals may exit the market in the next 3-5 years due to the new standards [4]. Group 4: Cost Implications for Companies - Companies may face increased research costs for safety evaluations, typically ranging from hundreds of thousands to millions of yuan per product [6]. - However, this is not expected to lead to significant price increases for TCM products due to market competition and the potential for cost dilution through scale production [6]. - The top 100 TCM products account for over 60% of the market share, indicating that leading companies with solid research foundations can manage the costs effectively [6]. Group 5: Support Mechanisms - National and provincial drug regulatory authorities have established communication mechanisms and green channels to support companies in conducting necessary research and expedite the review of supplementary applications for urgently needed products [7].

记者丨 唐唯珂 编辑丨季媛媛 中成药淘汰赛序幕拉开！大批中成药将退出市场。 距离2026年7月1日仅剩半年时间，国家药监局《中药注册管理专门规定》第七十五条的 落地进入最后窗口期。 这一被业内称为中成药"生死条款"的规定明确，自2023年7月1日施行满三年起，说明书 【禁忌】【不良反应】【注意事项】任意一项仍标注"尚不明确"的中成药，再注册申请 将依法不予通过。这意味着，国内现存约5 . 7万个中成药有效批准文号中，超7 0%存在安 全信息标注问题的批文将面临淘汰，一场由监管驱动的中药产业深度出清正式进入攻坚 阶段。 此次监管新政的核心，是彻底终结中成药说明书长期以来的"尚不明确"时代，倒逼药品 持有人补齐上市后安全数据短板。 中国食品药品监管杂志此前研究显示，2018年版《国家基本药物目录》中2 6 8个中成药品 种的465份说明书里，不良反应、禁忌、药物相互作用的标注率仅为2 0 . 6 4%、3 0 . 1%和 1 . 0 7% ， 大 量 品 种 依 靠 模 糊 表 述 完 成 上 市 后 的 市 场 流 通 。 而 随 着 再 注 册 大 考 临 近 ， 这 种"模糊免责"的模式已彻底失去生存空间。 ...